-
4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine trihydrochloride
-
ChemBase ID:
132860
-
Molecular Formular:
C18H22Cl3FN6
-
Molecular Mass:
447.7648832
-
Monoisotopic Mass:
446.09555599
-
SMILES and InChIs
SMILES:
c1cc(ccc1c1c(n(cn1)C1CCNCC1)c1ccnc(n1)N)F.Cl.Cl.Cl
Canonical SMILES:
Nc1nccc(n1)c1n(cnc1c1ccc(cc1)F)C1CCNCC1.Cl.Cl.Cl
InChI:
InChI=1S/C18H19FN6.3ClH/c19-13-3-1-12(2-4-13)16-17(15-7-10-22-18(20)24-15)25(11-23-16)14-5-8-21-9-6-14;;;/h1-4,7,10-11,14,21H,5-6,8-9H2,(H2,20,22,24);3*1H
InChIKey:
IPFBHUGKKONHFR-UHFFFAOYSA-N
-
Cite this record
CBID:132860 http://www.chembase.cn/molecule-132860.html
NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
4-[4-(4-fluorophenyl)-1-(piperidin-4-yl)-1H-imidazol-5-yl]pyrimidin-2-amine trihydrochloride
|
|
|
IUPAC Traditional name
|
4-[5-(4-fluorophenyl)-3-(piperidin-4-yl)imidazol-4-yl]pyrimidin-2-amine trihydrochloride
|
|
|
Synonyms
|
5-(2-Aminopyrimidin-4-yl)-4-(4-fluorophenyl)-1-(4-piperidinyl)imidazole trihydrochloride
|
SB 220025 trihydrochloride
|
|
|
CAS Number
|
|
MDL Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
Acid pKa
|
16.378748
|
H Acceptors
|
5
|
H Donor
|
2
|
LogD (pH = 5.5)
|
-1.5171407
|
LogD (pH = 7.4)
|
-0.83588886
|
Log P
|
1.7774142
|
Molar Refractivity
|
94.9989 cm3
|
Polarizability
|
37.97174 Å3
|
Polar Surface Area
|
81.65 Å2
|
Rotatable Bonds
|
3
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
Sigma Aldrich
Sigma Aldrich -
S9070
|
Biochem/physiol Actions SB 220025 is a potent, specific inhibitor of human p38 mitogen-activated protein (MAP) kinase, with an IC50 value of 60 nM and 50- to 1000-fold selectivity. SB 220025 reduces inflammatory cytokine production and inhibits angiogenesis. SB 220025 reduced the lipopolysaccharide-induced production of TNF at an ED50 value of 7.5 mg/kg. At 30 mg/kg, SB 220025 reduced the expression of TNF and inhibited angiogenesis by ~40%. In a further study, the effects of p38/CSBP MAP kinase inhibition in angiogenesis-dependent chronic inflammatory disease was tested in murine collagen-induced arthritis and SB 220025 was able to prevent the progression of established arthritis. |
PATENTS
PATENTS
PubChem Patent
Google Patent